Large-cap Health Care company argenx SE has logged a -1.9% change today on a trading volume of 1,079,602. The average volume for the stock is 353,160.
argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany, France, Canada, the United Kingdom, and Italy. Based in Amsterdam, Netherlands the company has 843 full time employees and a market cap of $26,271,746,048.
The company is now trading -35.55% away from its average analyst target price of $515.7 per share. The 20 analysts following the stock have set target prices ranging from $370.0 to $612.0, and on average give argenx SE a rating of buy.
Over the last 12 months ARGX shares have declined by -11.6%, which represents a difference of -34.5% when compared to the S&P 500. The stock's 52 week high is $550.76 per share and its 52 week low is $327.73. With its net margins declining an average -58.7% over the last 0 years, argenx SE declining profitability gives us reason to believe its stock price will continue to underwhelm.
| Date Reported | Total Revenue ($ k) | Net Profit ($ k) | Net Margins (%) |
|---|---|---|---|
| 2023 | 10,026 | -123,239 | -1229 |
| 2022 | 497,277 | 80,768 | 16 |
| 2021 | 497,277 | 80,768 | 16 |
| 2020 | 78,462 | -162,965 | -208 |
| 2019 | 78,462 | -66,641 | -85 |
| 2018 | 36,415 | -28,076 | -77 |
